CO7240407A2 - Formas cristalinas de un modulador del receptor androgénico - Google Patents

Formas cristalinas de un modulador del receptor androgénico

Info

Publication number
CO7240407A2
CO7240407A2 CO14270612A CO14270612A CO7240407A2 CO 7240407 A2 CO7240407 A2 CO 7240407A2 CO 14270612 A CO14270612 A CO 14270612A CO 14270612 A CO14270612 A CO 14270612A CO 7240407 A2 CO7240407 A2 CO 7240407A2
Authority
CO
Colombia
Prior art keywords
receptor modulator
androgenic receptor
crystal forms
androgenic
modulator
Prior art date
Application number
CO14270612A
Other languages
English (en)
Inventor
Nicholas D Smith
Mark R Herbert
Ouathek Ouerfelli
Anna Dilhas
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Intitute For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7240407(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Intitute For Cancer Res filed Critical Aragon Pharmaceuticals Inc
Publication of CO7240407A2 publication Critical patent/CO7240407A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En la presente descripción se describe formas amorfas y cristalinas del modulador delreceptor androgénico 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida. Además, se describen composicionesfarmacéuticas adecuadas para administrar a un mamífero 5 que incluyen el modulador delreceptor androgénico y métodos para usar el modulador del receptor androgénico, soloo en conjunto con otros compuestos, para tratar enfermedades o afecciones asociadascon la actividad del receptor androgénico.
CO14270612A 2012-06-07 2014-12-09 Formas cristalinas de un modulador del receptor androgénico CO7240407A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07

Publications (1)

Publication Number Publication Date
CO7240407A2 true CO7240407A2 (es) 2015-04-17

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14270612A CO7240407A2 (es) 2012-06-07 2014-12-09 Formas cristalinas de un modulador del receptor androgénico

Country Status (42)

Country Link
US (8) US9481663B2 (es)
EP (4) EP3348553B1 (es)
JP (3) JP6182209B2 (es)
KR (2) KR102195916B1 (es)
CN (3) CN113135892A (es)
AU (3) AU2013271751B2 (es)
BR (1) BR112014030678A2 (es)
CA (4) CA3008345C (es)
CL (1) CL2014003331A1 (es)
CO (1) CO7240407A2 (es)
CR (2) CR20190331A (es)
CY (3) CY1120393T1 (es)
DK (3) DK3533792T3 (es)
EA (3) EA201992010A1 (es)
EC (1) ECSP14030098A (es)
ES (3) ES2875932T3 (es)
FR (1) FR21C1050I1 (es)
GT (1) GT201400283A (es)
HK (2) HK1210175A1 (es)
HR (3) HRP20180902T1 (es)
HU (4) HUE050357T2 (es)
IL (4) IL236055A0 (es)
IN (1) IN2014DN10084A (es)
LT (4) LT3533792T (es)
ME (2) ME03815B (es)
MX (1) MX356754B (es)
MY (1) MY187500A (es)
NI (1) NI201400142A (es)
NO (1) NO2021046I1 (es)
NZ (2) NZ717683A (es)
PE (2) PE20150631A1 (es)
PH (2) PH12014502714B1 (es)
PL (3) PL3533792T3 (es)
PT (3) PT2858985T (es)
RS (3) RS57370B1 (es)
SG (3) SG11201408140QA (es)
SI (3) SI3348553T1 (es)
TR (1) TR201808939T4 (es)
TW (1) TWI532732B (es)
UA (2) UA115665C2 (es)
WO (1) WO2013184681A1 (es)
ZA (1) ZA201500076B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP3670561B1 (en) 2009-01-12 2023-12-06 University Of Massachusetts Lowell Polyisobutylene-based polyurethanes
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
PL3533792T3 (pl) 2012-06-07 2021-11-29 Aragon Pharmaceuticals, Inc. Postacie krystaliczne modulatora receptora androgenowego
KR102225416B1 (ko) 2012-09-11 2021-03-09 메디베이션 프로스테이트 테라퓨틱스 엘엘씨 엔잘루타마이드 제제
AU2013323861C1 (en) 2012-09-26 2024-05-02 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JP2015535538A (ja) 2012-11-21 2015-12-14 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ 高強度ポリイソブチレンポリウレタン
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2017525727A (ja) * 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
EP3226842B1 (en) 2014-12-05 2020-11-25 Aragon Pharmaceuticals, Inc. Anticancer compositions
MA41111B1 (fr) 2014-12-05 2021-09-30 Aragon Pharmaceuticals Inc Compositions anticancéreuses
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
EP3235345B1 (en) 2014-12-19 2024-03-06 Lutron Technology Company LLC Multi-channel lighting fixture having multiple light-emitting diode drivers
PE20181925A1 (es) 2016-06-03 2018-12-11 Aragon Pharmaceuticals Inc Composiciones antineoplasicas
RU2019121700A (ru) 2016-12-13 2021-01-15 Ватсон Лэборетериз Инк. Твердые формы апалутамида
EP3592786B1 (en) 2017-03-07 2023-05-10 Cardiac Pacemakers, Inc. Hydroboration/oxidation of allyl-terminated polyisobutylene
US10835638B2 (en) 2017-08-17 2020-11-17 Cardiac Pacemakers, Inc. Photocrosslinked polymers for enhanced durability
EP3697398A1 (en) 2017-10-16 2020-08-26 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
CN111479596B (zh) 2018-01-17 2023-04-07 心脏起搏器股份公司 封端聚异丁烯聚氨酯
US20200270226A1 (en) * 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) * 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) * 2019-08-22 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4208451A1 (en) 2020-09-04 2023-07-12 Synthon B.V. Improved process for preparation of apalutamide
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634A (zh) * 2022-10-17 2022-12-30 上海博悦生物科技有限公司 一种阿帕他胺的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
LT3412290T (lt) 2006-03-27 2021-04-26 The Regents Of The University Of California Androgeno receptorių moduliatorius, skirtas prostatos vėžio bei su androgeno receptoriais susijusių ligų gydymui
KR101456722B1 (ko) * 2006-03-29 2014-10-31 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EA028869B1 (ru) * 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
PL3533792T3 (pl) 2012-06-07 2021-11-29 Aragon Pharmaceuticals, Inc. Postacie krystaliczne modulatora receptora androgenowego
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof

Also Published As

Publication number Publication date
EP3922629A1 (en) 2021-12-15
US20190330182A1 (en) 2019-10-31
HUS2100047I1 (hu) 2021-11-29
EP3348553A1 (en) 2018-07-18
US10526310B2 (en) 2020-01-07
CA3055660A1 (en) 2013-12-12
CA3008345A1 (en) 2013-12-12
KR102195916B1 (ko) 2020-12-30
IL275413A (en) 2020-07-30
IL236055A0 (en) 2015-02-01
SI3348553T1 (sl) 2020-11-30
US10766875B2 (en) 2020-09-08
KR20150021993A (ko) 2015-03-03
CY1120393T1 (el) 2019-07-10
NZ702203A (en) 2016-09-30
RS61988B1 (sr) 2021-07-30
HRP20180902T1 (hr) 2018-08-24
PE20150631A1 (es) 2015-05-11
RS60617B1 (sr) 2020-09-30
JP2015518890A (ja) 2015-07-06
PE20200725A1 (es) 2020-07-21
DK3533792T3 (da) 2021-06-28
DK3348553T3 (da) 2020-07-27
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
HUE038082T2 (hu) 2018-09-28
GT201400283A (es) 2017-07-03
DK2858985T3 (en) 2018-05-28
ES2875932T3 (es) 2021-11-11
AU2017200298B2 (en) 2017-09-28
ECSP14030098A (es) 2016-01-29
US10556882B2 (en) 2020-02-11
US20170001977A1 (en) 2017-01-05
TR201808939T4 (tr) 2018-07-23
EA201492272A1 (ru) 2015-05-29
CR20140549A (es) 2015-04-06
IL259738A (en) 2018-07-31
MX356754B (es) 2018-06-11
JP2017178923A (ja) 2017-10-05
JP6345821B2 (ja) 2018-06-20
EA201791592A1 (ru) 2018-01-31
EP2858985B1 (en) 2018-04-18
AU2017200298A1 (en) 2017-02-02
LT3348553T (lt) 2020-09-25
CA2875767A1 (en) 2013-12-12
EP2858985A1 (en) 2015-04-15
US9481663B2 (en) 2016-11-01
MX2014015005A (es) 2015-09-04
US20150133481A1 (en) 2015-05-14
HRP20201387T1 (hr) 2020-11-27
MY187500A (en) 2021-09-24
TW201402561A (zh) 2014-01-16
CA3008345C (en) 2019-10-22
EP3533792B1 (en) 2021-05-05
PL2858985T3 (pl) 2018-09-28
IL267608A (en) 2019-08-29
SG11201408140QA (en) 2015-01-29
IN2014DN10084A (es) 2015-08-21
CY1124831T1 (el) 2022-03-24
SG10201610249TA (en) 2017-02-27
PT2858985T (pt) 2018-07-10
SI2858985T1 (sl) 2018-12-31
NZ717683A (en) 2018-04-27
UA123142C2 (uk) 2021-02-24
UA115665C2 (uk) 2017-12-11
US20210163441A1 (en) 2021-06-03
KR102062024B1 (ko) 2020-01-03
JP6182209B2 (ja) 2017-08-16
EA201992010A1 (ru) 2020-01-24
EP3348553B1 (en) 2020-07-08
EP2858985A4 (en) 2016-05-25
PL3348553T3 (pl) 2021-02-08
CA2875767C (en) 2018-08-14
NO2021046I1 (no) 2021-11-02
CA3114726A1 (en) 2013-12-12
US9994545B2 (en) 2018-06-12
CR20190331A (es) 2019-11-12
KR20190132543A (ko) 2019-11-27
JP2018141009A (ja) 2018-09-13
US20190241539A1 (en) 2019-08-08
SG10201610248SA (en) 2017-02-27
CY1123427T1 (el) 2021-12-31
HUE054595T2 (hu) 2021-09-28
HRP20210909T1 (hr) 2021-09-03
BR112014030678A2 (pt) 2017-06-27
US20200354335A1 (en) 2020-11-12
TWI532732B (zh) 2016-05-11
EA028791B1 (ru) 2017-12-29
US20180258067A1 (en) 2018-09-13
ES2809738T3 (es) 2021-03-05
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
EA033956B1 (ru) 2019-12-13
EP3533792A1 (en) 2019-09-04
PT3533792T (pt) 2021-06-07
HK1210175A1 (en) 2016-04-15
AU2013271751B2 (en) 2017-02-23
AU2017279807A1 (en) 2018-01-25
WO2013184681A1 (en) 2013-12-12
US10308630B2 (en) 2019-06-04
PH12016501470B1 (en) 2017-07-10
PH12016501470A1 (en) 2017-07-10
CN113135892A (zh) 2021-07-20
US20200115361A1 (en) 2020-04-16
ZA201500076B (en) 2016-10-26
LTPA2021525I1 (es) 2021-11-25
PH12014502714A1 (en) 2015-02-02
IL259738B (en) 2021-06-30
ME03815B (me) 2021-04-20
AU2013271751A1 (en) 2014-12-18
CN104619692A (zh) 2015-05-13
RS57370B1 (sr) 2018-08-31
ME03081B (me) 2019-01-20
CN105693692A (zh) 2016-06-22
LT3533792T (lt) 2021-07-26
PT3348553T (pt) 2020-09-28
AU2017279807B2 (en) 2018-11-08
PL3533792T3 (pl) 2021-11-29
LT2858985T (lt) 2018-09-25
FR21C1050I1 (fr) 2021-12-10
PH12014502714B1 (en) 2015-02-02
SI3533792T1 (sl) 2021-11-30
HK1226066A1 (zh) 2017-09-22
CL2014003331A1 (es) 2016-03-04

Similar Documents

Publication Publication Date Title
CO7240407A2 (es) Formas cristalinas de un modulador del receptor androgénico
NZ702663A (en) Nuclear transport modulators and uses thereof
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
GT201300215A (es) Inhibidores de glucosilceramida sintasa
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
EA201690582A1 (ru) Модуляторы фактора в комплемента
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
NI201500050A (es) Benzamidas
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
CL2009000876A1 (es) Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
MX2015012043A (es) Agonistas muscarinicos.
CL2011003050A1 (es) Compuestos derivados de 17beta-alquil-17alfa-oxi-estratrienos sustituidos; compuestos intermediarios derivados de oxitrienos; composicion farmaceutica; utiles en el tratamiento de trastornos dependientes del estrogeno.
CL2015002906A1 (es) Suministro al sistema nervioso central de agentes terapéuticos (divisional de solicitud 3656-2012)
CL2011002626A1 (es) Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos.